Consensus LifeMD, Inc.

Stocks

LFMD

US53216B1044

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 21:00:00 23/10/2026 BST			5-day change	1st Jan Change
2.130 ^USD	-1.84%		-8.97%	-37.54%

08-06	B. Riley Adjusts Price Target on LifeMD to $8 From $10, Maintains Buy Rating	MT
08-05	LifeMD, Inc., Q2 2026 Earnings Call, Aug 05, 2026

Evolution of the Average Target: LifeMD, Inc.

Evolution of the Target Price: LifeMD, Inc.

Changes in Analyst Recommendations: LifeMD, Inc.

a1887d40ce1ec3add.EMvtHDmGednP0811UkUybyf-pK3ntIy94JekT_QB9o4.RqfULlj3CbCDv4ctZRVkKEamyOaT4-6P1dvLALBNgtpd5r9IUfAAjIzmiA~22a29449e2e62654ffa95501adc83511

Analysts' recommendations: LifeMD, Inc.

08-06	B. Riley Adjusts Price Target on LifeMD to $8 From $10, Maintains Buy Rating	MT
03-16	Mizuho Upgrades LifeMD to Outperform From Neutral, Adjusts Price Target to $8 From $6	MT
01-16	Novo's Wegovy pill makes encouraging start in weight-loss race vs Lilly	RE
01-05	Sector Update: Health Care Stocks Decline Late Afternoon	MT
11-18	B. Riley Adjusts Price Target on LifeMD to $10 From $12, Maintains Buy Rating	MT
08/01/25	KeyBanc Cuts Price Target on LifeMD to $7.50 From $10, Keeps Overweight Rating	MT
04/12/24	Mizuho Initiates LifeMD at Neutral With $7 Price Target	MT
08/11/24	B. Riley Adjusts Price Target on LifeMD to $12 From $11, Maintains Buy Rating	MT
08/08/24	B. Riley Trims Price Target on LifeMD to $11 From $12, Maintains Buy Rating	MT
11/07/24	KeyBanc Adjusts Price Target on LifeMD to $10 From $12, Maintains Overweight Rating	MT
05/06/24	KeyBanc Initiates LifeMD at Overweight With $12 Price Target, Cites 'Strong Top & Bottom-Line Growth'	MT
09/05/24	Cantor Fitzgerald Adjusts LifeMD's Price Target to $15 From $13, Keeps Overweight Rating	MT
23/04/24	BTIG Adjusts LifeMD's Price Target to $14 From $13, Keeps Buy Rating	MT
12/03/24	Craig-Hallum Adjusts LifeMD's Price Target to $15 From $10, Maintains Buy Rating	MT
12/03/24	Cantor Fitzgerald Adjusts Price Target on LifeMD to $11 From $9, Maintains Overweight Rating	MT
12/03/24	B. Riley Securities Lifts LifeMD's PT to $12 From $11 After 'Strong' Q4 2023 Results, Maintains Buy Rating	MT
11/01/24	HC Wainwright Adjusts LifeMD Price Target to $12 From $10, Maintains Buy Rating	MT
14/11/23	Cantor Fitzgerald Adjusts LifeMD's Price Target to $9 From $8, Maintains Overweight Rating	MT
09/11/23	HC Wainwright Adjusts Price Target on LifeMD to $10 From $9, Maintains Buy Rating	MT
09/11/23	B. Riley Raises LifeMD's Price Target to $11 From $7 After Q3 Topline Beat, Maintains Buy Rating	MT
02/10/23	Cantor Fitzerald Adjusts LifeMD Price Target to $8 From $7, Maintains Overweight Rating	MT
21/07/23	Cantor Fitzgerald Starts LifeMD at Overweight With $7 Price Target	MT
10/07/23	B. Riley Raises LifeMD's PT to $7 From $3.50 on Increased Conviction for Durable Growth, Enhanced EBITDA; Keeps Buy Rating	MT
03/07/23	HC Wainwright Initiates LifeMD With Buy Rating, $9 Price Target	MT
23/03/23	BTIG Research Adjusts LifeMD Price Target to $7 From $8, Maintains Buy Rating	MT

More recommendations

Medical Software & Technology Services

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	LIFEMD, INC.					+274.42%
	THERMO FISHER SCIENTIFIC, INC.					+8.72%
	DANAHER CORPORATION					+12.67%
	INTUITIVE SURGICAL, INC.					+8.17%
	BOSTON SCIENTIFIC CORPORATION					+26.06%
	SIEMENS HEALTHINEERS AG					+8.7%
	VEEVA SYSTEMS INC.					-7.39%
	EDWARDS LIFESCIENCES CORPORATION					+12.54%
	AGILENT TECHNOLOGIES, INC.					+3.85%
	WATERS CORPORATION					+2.26%
	Average					+35.00%
	Weighted average by Cap.					+9.36%